We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
Dr. Francesco Piraino, Scientist Bioengineer - Quanterix, Inc,
"Monitoring Health and Disease Progression with Utrasensitive Biomarker Analysis"
Quanterix Simoa™ technology detects proteins with 1000]fold higher sensitivity than traditional immunoassays
ltrasensitive detection is enabling the identification of more informative biomarkers requiring less invasive and less expensive testing proceduresto improve our understanding of neurodegenerative disease.Simoa assays are currently applied across various therapeutic areas including neurology, oncology, cardiology, inflammation and infectiousdisease to detect biomarkers in a variety of sample matrices.Quanterix cytokine assays lead the field with respect to precision, disease correlation and detection of endogenous analytes.Quanterix offers a large menu of commercially available assays, an open instrument platform for developing homebrew assays, and assay testing services.
BIO: Francesco Piraino is a research scientist at the Swiss Federal Institute of Technology in Lausanne (Switzerland). He uses microscale technologies to develop next-generation microfluidic diagnostics platforms. Following his graduate studies in Biomedical Engineering at Politecnico di Milano (Italy) and at Harvard-MIT Division of Health Science & Technology (USA), he joined the Broad Institute of MIT and Harvard (USA) to develop devices for single-cell genomics. Dr. Piraino is a trained bioengineer who has also attended programs at the Universitat de Barcelona (Spain), the CityCollege of the City University of New York (USA), and the Massachusetts Institute of Technology (USA). His work aims to solve problems at the intersection of biomedical engineering and medicine.
Host: Clinical Neuroimmunology, manuel.comabella@vhir.org
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.